fda compounding semaglutide warning letters september 2025 Last month, the issued 25 to telehealth companies over what it called false or misleading claims about compounded GLP-1 medications. Read more at the link in the comments below FDA issued a warning letter

[1] [2] It works by mimicking the incretin hormone GLP-1, which stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways

BPC 157 is not currently approved by the FDA for medical use but can be obtained in some regions for research purposes

More absorbable Glutathione When taken orally, standard glutathione is poorly absorbed

Individuals at risk of AD or with diabetes may be in the early or middle biological stage of AD, offering a greater opportunity for GLP-1RAs to provide neuroprotection

Women experience GI side effects at up to 2.5 times the rate of men

Congrats on the BPC fairly wild when the FDA only could identify 3 total cases of negative impact in their database related to bpc-157 Big news for the American people